Angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), β-blockers, and mineralocorticoid receptor antagonists (MRA) are considered the cornerstone for the treatment of patients suffering from heart failure with reduced ejection fraction (HFrEF), as these approaches can facilitate left ventricular reverse remodeling (LVRR), minimize the hospital admission rate of patients with heart failure (HF), and decrease the overall rates of mortality and cardiovascular mortality, including those related to sudden cardiac death (SCD) (1–5). This evidence concerns the gene NR3C2 and heart failure.